Prescribing medication errors in hospitalised patients: A prospective study

Acta Pharmaceutica

Volumn 55, Issue 2, 2005, Pages 157-167

  Vrca, Vesna Bačić ^a,b   Bećirević Laćan, Mira ^b   Boz̧ikov, Velimir ^a,b   Biruš, Mladen ^b  

^a University of Zagreb School of Medicine   (Croatia)

^b UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

Drug interactions; Hospitalised patients; Medication errors; Prescribing; Prospective study

Indexed keywords

ALLOPURINOL; AMILORIDE; AMIODARONE; ANTIBIOTIC AGENT; DICLOFENAC; DIGOXIN; FUROSEMIDE; GENTAMICIN; HYDROCHLOROTHIAZIDE; INDOMETACIN; KETOCONAZOLE; KETOPROFEN; NIFEDIPINE; PROPAFENONE; RANITIDINE; THEOPHYLLINE; TRIAMTERENE; VERAPAMIL; WARFARIN;

ADULT; AGED; ARTICLE; BLEEDING; BRADYCARDIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DOSE RESPONSE; DRUG DISTRIBUTION; DRUG MONITORING; DRUG OVERDOSE; DRUG TOXICITY; ECG ABNORMALITY; FEMALE; HEARING LOSS; HEART VENTRICLE EXTRASYSTOLE; HOSPITAL CARE; HUMAN; HYPERKALEMIA; INCIDENCE; KIDNEY FAILURE; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MEDICAL SOCIETY; MEDICATION ERROR; NAUSEA; NEPHROTOXICITY; OTOTOXICITY; PHARMACIST; PHYSICIAN; PRESCRIPTION; SIDE EFFECT; VOMITING;

EID: 22244456752     PISSN: 13300075     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. M. R. Cohen, Medication Errors, American Pharmaceutical Association, Washington D.C. 1999, pp. 2.1-2.4.
2. M. F. Conlan, Medical errors, Hosp. Pharm. Rep. 14 (2000) 41-44.
3. M. A. Sweeney, Physician-pharmacist collaboration: a millennial paradigm to reduce medication errors, J. Am. Osteopath. Assoc. 102 (2002) 678-681.
4. N. M. LaPointe and J. G. Jollis, Medication errors in hospitalized cardiovascular patients, Arch. Intern. Med. 163 (2003) 1461-1466.
5. M. L. Jenkinson, Prescribing errors, Lancet 360 (2002) 256-259.
6. S. Hennessy, W. B. Bilker, L. Zhou, A. L. Weber, C. Brensinger, Y. Wang and B. L. Strom, Retrospective drug utilization review, prescribing errors, and clinical outcomes, JAMA 290 (2003) 1494-1499.
7. L. L. Leape, D. W. Bates and D. J. Cullen, System analysis of adverse drug events, JAMA 274 (1995) 35-43.
8. J. H. Gurwitz, T. S. Field, J. Judge, P. Rochon, L. R. Harrold, C. Cadoret, M. Lee, K. White, J. LaPrino, J. Erramuspe-Mainard, M. DeFlorio, L. Gavendo, J. Auger and D. W. Bates, The incidence of the adverse drug events in two large academic long-term care facilities, Am. J. Med. 118 (2005) 251-258.
9. AHFS first Web version 2, American Society of Health System Pharmacists, Indianapolis 2002.
10. B. Vrhovac and Ž. Reiner, Farmakoterapijski priručnik 3, Med-Ekon, Zagreb 2000.
11. L. Bencarić, Register of Drugs in Croatia, 45th ed., Healthcare Employers, Zagreb 2002.
12. rd ed. (Eds. R. Walker and C. Edwards) Edinburgh 2003 pp. 21-32.
13. G. G. Belz, W. Doering, R. Munkes and J. Matthews, Interaction between digoxin and calcium antagonists and antiarrhythmic drugs, Clin. Pharmacol. Ther. 33 (1983) 410-417.
14. M. V. Calvo, A. Martin Suarez M. C. Avila and C. Martin Luengo, Digoxin-propafenone interaction, Med. Clin. (Barcelona) 89 (1987) 171-172.
15. J. O. Moysey, N. S. Jaggarao, E. N. Grundy and D. A. Chamberlain, Amiodarone increases plasma digoxin concentrations, Br. Med. J. 282 (1981) 272-275.
16. P. Douste-Blazy, J. L. Montastruc, B. Bonnet, P. Auriol, D. Conte and P. Bernadet, Influence of amiodarone on plasma and urine digoxin concentrations, Lancet 1 (1984) 905-907.
17. K. E. Pedersen, A. Dorph-Pedersen, S. Hvidt, N. A. Klitgaard and F. Nielsen-Kudsk, Digoxin-verapamil interaction, Clin. Pharmacol. Ther. 30 (1981) 311-316.
18. H. O. Klein, R. Lang, E. Weiss, E. Di Segni, C. Libhaber, J. Guerrero and E. Kaplinsky, The influence of verapamil on serum digoxin concentration, Circulation 65 (1982) 998-1003.
19. H. O. Klein and E. Kaplinsky, Verapamil and digoxin: their respective effects on atrial fibrillation and their interaction. Am. J. Cardiol. 50 (1982) 894-902.
20. R. L. Manfredi and E. S. Vesell, Inhibition of theophylline metabolism by long-term allopurinol administration, Clin. Pharmacol. Ther. 29 (1981) 224-229.
21. M. Barry and J. Feely, Allopurinol influences aminophenazone elimination, Clin. Pharmacokin. 19 (1990) 167-169.
22. J. J. Grygiel, L. M. Wing, J. Farkas and D. J. Birkett, Effects of allopurinol on theophylline metabolism and clearance, Clin. Pharmacol. Ther. 26 (1979) 660-667.
23. S. Vozeh, J. R. Powell, G. C. Cupit, S. Riegelman and L. B. Sheiner, Influence of allopurinol on theophylline disposition in adults, Clin. Pharmacol. Ther. 27 (1980) 194-197.
24. S. Almog, N. Shafran, H. Halkin, P. Weiss, Z. Farfel, U. Martinowitz and H. Bank, Mechanism of warfarin potentiation by amiodarone: dose-and concentration-dependent inhibition of warfarin elimination, Eur. J. Clin. Pharmacol. 28 (1985) 257-261.
25. A. Rees, J. J. Dalal, P. G. Reid, A. H. Henderson and M. J. Lewis, Dangers of amiodarone and anticoagulant treatment, Br. Med. J. (Clin. Res. Ed.) 282 (1981) 1756-1757.
26. R. A. O'Reilly, W. F. Trager, A. E. Rettie and D. A. Goulart, Interaction of amiodarone with racemic warfarin and its separated enantiomorphs in humans, Clin. Pharmacol. Ther. 42 (1987) 290-294.
27. L. D. Heimark, L. Wienkers, K. Kunze, M. Gibaldi, A. C. Eddy, W. F. Trager, R. A. O'Reilly and D. A. Goulart, The mechanism of the interaction between amiodarone and warfarin in humans, Clin. Pharmacol. Ther. 51 (1992) 398-407.
28. R. H. Mathog and W. J. Klein, Jr., Ototoxicity of ethacrynic acid and aminoglycoside antibiotics in uremia, N. Engl. J. Med. 280 (1969) 1223-1224.
29. W. D. Meriwether, R. J. Mangi and A. A. Serpick, Deafness following standard intravenous dose of ethacrynic acid, JAMA 216 (1971) 795-798.
30. S. C. Piscitelli, T. F. Goss, J. H. Wilton, D. T. D'Andrea, H. Goldstein and J. J. Schentag, Effects of ranitidine and sucralfate on ketoconazole bioavailability, Antimicrob. Agents Chemother. 35 (1991) 1765-1771.
31. S. G. Lim, A. M. Sawyerr, M. Hudson, J. Sercombe and R. E. Pounder, Short report: the absorption of fluconazole and itraconazole under conditions of low intragastric acidity, Aliment. Pharmacol. Ther. 7 (1993) 317-321.
32. A. Mathews and G. R. Bailie, Acute renal failure and hyperkalemia associated with triamterene and indomethacin, Vet. Hum. Toxicol. 28 (1986) 224-225.
33. M. Harkonen and S. Ekblom-Kullberg, Reversible deterioration of renal function after diclofenac in patient receiving triamterene, Br. Med. J. 293 (1986) 698-699.
34. T. W. B. Gehr, D. A. Sica, B. W. Steiger and C. Marshall, Interaction of triamterene-hydrochlorothiazide (T-H) and ibuprofen (I), Clin. Pharmacol. Ther. 47 (1990) 200-203.
35. K. N. Barker, E. A. Flynn, G. A. Pepper, D. W. Bates and R. L. Mikeal, Medication errors observed in 36 health care facilities, Arch. Intern. Med. 162 (2002) 1897-1903.
36. J. E. Fontan, V. Maneglier, V. X. Nguyen, C. Loirat and F. Brion, Medication errors in hospitals: computerised unit dose drug dispensing system versus ward stock distribution system, Pharm. World Sci. 25 (2003) 112-117.